US Patent

US8318706 — Substituted tetracycline compounds

Method of Use · Assigned to Paratek Pharmaceuticals Inc · Expires 2032-01-03 · 6y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects novel substituted tetracycline compounds that can be used to treat bacterial infections and neoplasms.

USPTO Abstract

The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms.

Drugs covered by this patent

sarecycline-hydrochloride (SARECYCLINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2405`	—	sarecycline-hydrochloride
`U-2405`	—	sarecycline-hydrochloride
`U-2405`	—	sarecycline-hydrochloride

Patent Metadata

Patent number: US8318706
Jurisdiction: US
Classification: Method of Use
Expires: 2032-01-03
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Paratek Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.